Suchergebnisse - "Ho, Alan L"

PubPharm (123)

1

Phase II, Single-Arm Trial of Induction and Concurrent Vismodegib With Curative-Intent Radiation Therapy for Locally Advanced, Unresectable Basal Cell Carcinoma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Barker, C. | Dufault, S. | Arron, S. | +8

2

Hypoxia-Directed Treatment of Human Papillomavirus-Related Oropharyngeal Carcinoma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Lee, N. | Sherman, E. | Schöder, H. | +39

3

Evolutionary dynamics of tipifarnib in HRAS mutated head and neck squamous cell carcinoma

enthalten in: Oral oncology | 2024

von Jagadeeshan, S. | Suryamohan, K. | Shin, N. | +20

4

NCCN Guidelines® Insights : Merkel Cell Carcinoma, Version 1.2024

enthalten in: Journal of the National Comprehensive Cancer Network : JNCCN | 2024

von Schmults, C. | Blitzblau, R. | Aasi, S. | +35

5

A phase 2 study of MK‐2206 in patients with incurable adenoid cystic carcinoma (Alliance A091104)

enthalten in: Cancer | 2024

von Ho, A. | Foster, N. | Deraje Vasudeva, S. | +6

6

Nivolumab plus ipilimumab in advanced salivary gland cancer : a phase 2 trial

enthalten in: Nature medicine | 2023

von Vos, J. | Burman, B. | Jain, S. | +26

7

Basal Cell Skin Cancer, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

enthalten in: Journal of the National Comprehensive Cancer Network : JNCCN | 2023

von Schmults, C. | Blitzblau, R. | Aasi, S. | +33

8

A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Hanna, G. | Ahn, M. | Muzaffar, J. | +11

9

The evolving landscape of salivary gland tumors

enthalten in: CA: a cancer journal for clinicians | 2023

von Steuer, C. | Hanna, G. | Viswanathan, K. | +5

10

Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity

enthalten in: Cancer research | 2023

von Smith, A. | Chan, S. | Wang, Z. | +20

CommentIn: Cancer Res. 2023 Oct 2;83(19):3162-3164. - PMID 37779427

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[13]